A Leading Authority Finds Lemtrada Causes Brain Bleeding

Lemtrada Stroke Lawsuit News

There are few more deadly and life-threatening conditions than those that adversely affect the brain or the nervous system. Multiple Sclerosis and Lemtrada affect them both

Thursday, May 30, 2019 - The Lancet Neurology, a leading authority on the study and treatment of disorders of the nervous system, has recently published the findings of a groundbreaking study on the adverse side effects of alemtuzumab, known by the brand name Lemtrada, a drug given to patients who suffer from relapse recurring multiple sclerosis (RRMS). The Lancet Neurology study uncovered complications other than and in addition to those that were alleged by the FDA. Intracranial hemorrhaging (IH) has also been found to occur at longer time intervals after Lemtrada treatments. Lemtrada stroke attorneys recommend a free consultation before filing a Lemtrada lawsuit claim.

The Cleveland Clinic describes intracranial hemorrhage as "a type of bleeding that occurs inside the skull (cranium). Bleeding around or within the brain itself is known as a cerebral hemorrhage (or intracerebral hemorrhage). Bleeding caused by a blood vessel in the brain that has leaked or ruptured (torn) is called a hemorrhagic stroke."

Two cases of intracranial hemorrhaging were uncovered by patients with RRMS that were given alemtuzumab infusions, one that occurred after 19 months and the other, resulting in a fatality, after 27 months. Five more cases were found that occurred within 24 hours of Lemtrada treatment. The Lancet reported "On Nov 29, 2018, the US Food and Drug Administration released a safety communication regarding 13 cases of ischaemic or hemorrhagic stroke and cervical arterial dissection associated with alemtuzumab treatment,9 12 of which occurred within one day of initiating treatment. We have retrospectively identified another five cases of spontaneous intracranial hemorrhage that occurred during the initial 5-day course of alemtuzumab administration, in four US multiple sclerosis centers, between March 2016, and October 2017."

Intracranial hemorrhage is a serious and life-threatening condition that develops quickly. The Cleveland Clinic warns Lemtrada patients to watch for the earliest possible symptoms such as "sudden tingling, weakness, numbness, paralysis, severe headache, difficulty with swallowing or vision, loss of balance or coordination, difficulty understanding, speaking, reading, or writing, and a change in level of consciousness or alertness, marked by stupor, lethargy, sleepiness, or coma." Lemtrada patients that experienced intracranial hemorrhage reported experiencing headaches, chest and neck pain.

In summary, the five new cases of Lemtrada-induced intracranial hemorrhage were females in their late 30's and 40s having suffered from RRMS for roughly 10-20 years. As noted in previous articles here, Lemtrada is given to RRMS patients as a last resort only when other drugs have failed. The patients all had been given two or more drugs before attempting alemtuzumab. The medical history of the patients in the study was thoroughly investigated beforehand, and other than suffering from RRMS were in relatively good health. "Our patients did not have a history of bleeding disorder; stroke; intracranial hemorrhage; aneurysm; hypertension; connective-tissue or rheumatological disease; or concomitant use of antihypertensives, anticoagulants, or platelet inhibitors."

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.